Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma

Endometrial cancer is one of the most common gynaecological cancers in both the United States and the Russian Federation, and the rate continues to rise. Although early-stage endometrial cancer is associated with a favourable 5-year survival rate (96%), this rate in patients with distant metastases accounts for only 18%. A combination of paclitaxel and carboplatin is standard first-line therapy for advanced, recurrent and metastatic endometrial carcinoma. Pembrolizumab, a monoclonal antibody targeting the programmed death-1 receptor, is approved for therapy of metastatic solid tumors with high microsatellite instability that have progressed aft er previous therapy and have no alternative treatment options. Lenvatinib is an oral multikinase inhibitor that blocks vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, platelet-derived growth factor receptor alpha, RET and KIT. Phase II and III studies (KEYNOTE-146/ Study111 and KEYNOTE-775) on the combination of lenvatinib and pembrolizumab in advanced endometrial carcinoma, irrespective of MMR and MSI status, have shown new potential for the treatment of this pathology. Th e results obtained, including progression-free and overall survival, allow the combination of lenvatinib and pembrolizumab to be considered a new standard for the treatment of this pathology.

1. Cote M.L., Ruterbusch J.J., Olson S.H., Lu K., Ali-Fehmi R. The growing burden of endometrial cancer: a major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev. 2015;24(9):1407–15. DOI: 10.1158/1055-9965.EPI-15-0316

2. Constantine G.D., Kessler G., Graham S., Goldstein S.R. Increased incidence of endometrial cancer following the women’s health initiative: an assessment of risk factors. J Womens Health (Larchmt). 2019;28(2):237–43. DOI: 10.1089/jwh.2018.6956

3. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. DOI: 10.1158/0008-5472.CAN-14-0155

4. Key statistics for endometrial cancer. American Cancer Society: [cited 2022 Oct 21]. Available from: https://www.cancer.org/cancer/endometrial-cancer/about/key-statistics.html.

5. Endometrial cancer survival rates, by stage. American Cancer Society: [cited 2022 Oct 21]. Available from: https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html.

6. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 3.2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.

7. Miller D.S., Filiaci V.L., Mannel R.S., Cohn D.E., Matsumoto T., Tewari K.S., et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–50. DOI: 10.1200/JCO.20.01076

8. Menshikov K.V., Sultanbaev A.V., Musin Sh.I., Menshikova I.A., Lipatov D.O., Sultanbaeva N.I., et al. Systemic therapy for advanced endometrial cancer. Literature review. Oncology Bulletin of the Volga region. 2021;12(1):31–43 (In Russ.).

9. Makker V., Green A.K., Wenham R.M., Mutch D., Davidson B., Miller D.S. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4:19. DOI: 10.1186/s40661-017-0056-7

10. Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14(2):357–61. DOI: 10.1200/JCO.1996.14.2.357

11. Keytruda (pembrolizumab). Whitehouse Station, NJ: Merck Sharp & Dohme; 2018.

12. Arora E., Masab M., Mittar P., Jindal V., Gupta S., Dourado C. Role of immune checkpoint inhibitors in advanced or recurrent endometrial cancer. Cureus. 2018;10(4):e2521. DOI: 10.7759/cureus.2521

13. Bell D.W., Ellenson L.H. Molecular genetics of endometrial carcinoma. Annu Rev Pathol. 2019;14:339–67. DOI: 10.1146/annurevpathol-020117-043609

14. O’Malley D.M., Bariani G.M., Cassier P.A., Marabelle A., Hansen A.R., De Jesus Acosta A., et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61. DOI: 10.1200/JCO.21.01874

15. Marabelle A., Le D.T., Ascierto P.A., Di Giacomo A.M., De JesusAcosta A., Delord J.P., et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repairdeficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. DOI: 10.1200/JCO.19.02105

16. Soumerai T.E., Donoghue M.T.A., Bandlamudi C., Srinivasan P., Chang M.T., Zamarin D., et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24(23):5939–47. DOI: 10.1158/1078-0432.CCR-18-0412

17. Ott P.A., Bang Y.J., Berton-Rigaud D., Elez E., Pishvaian M.J., Rugo H.S., et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41. DOI: 10.1200/JCO.2017.72.5952

18. Suyama K., Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25(1):1073274818789361. DOI: 10.1177/1073274818789361

19. Okamoto K., Kodama K., Takase K., Sugi N.H., Yamamoto Y., Iwata M., et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103. DOI: 10.1016/j.canlet.2013.07.007

20. Ferrari S.M., Ruffilli I., Centanni M., Virili C., Materazzi G., Alexopoulou M., et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat Anticancer Drug Discov. 2018;13(2):201–8. DOI: 10.2174/1574892813666180220110729

21. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. DOI: 10.1016/j.ejca.2008.10.026

22. Vergote I., Powell M.A., Teneriello M.G., Miller D.S., Garcia A.A., Mikheeva O.N., et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020;156(3):575–82. DOI: 10.1016/j.ygyno.2019.12.039

23. Kato Y., Tabata K., Kimura T., Yachie-Kinoshita A., Ozawa Y., Yamada K., et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. DOI: 10.1371/journal.pone.0212513

24. Kato Y., Bao X., Macgrath S., Tabata K., Hori Y., Tachino S., et al. Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response. Ann Oncol. 2016;27(suppl 6): abstr 2PD. DOI: 10.1093/annonc/mdw362.02

25. Kimura T., Kato Y., Ozawa Y., Kodama K., Ito J., Ichikawa K., et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993–4002. DOI: 10.1111/cas.13806

26. Taylor M., Dutcus C.E., Schmidt E., Bagulho T., Li D., Shumaker R., et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Ann Oncol. 2016;27(suppl 6): abstr 776PD. DOI: 10.1093/annonc/mdw373.04

27. Makker V., Rasco D., Vogelzang N.J., Brose M.S., Cohn A.L., Mier J., et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label single-arm, phase 2 trial. Lancet Oncol. 2019;20(5):711–8. DOI: 10.1016/S1470-2045(19)30020-8

28. Makker V., Taylor M.H., Aghajanian C., Oaknin A., Mier J., Cohn A.L., et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–92. DOI: 10.1200/JCO.19.02627

29. Oaknin A., Duska L.R., Sullivan R.J., Pothuri B., Ellard S.L., Leath C.A. III, et al. Preliminary safety, efficacy, and pharmacokinetic/ pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer. Gynecol Oncol. 2019;154(suppl 1): abstr 33. DOI:10.1016/j.ygyno.2019.04.044

30. Konstantinopoulos P.A., Luo W., Liu J.F., Gulhan D.C., Krasner C., Ishizuka J.J., et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/ persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–94. DOI: 10.1200/JCO.19.01021

31. Antill Y., Kok P.S., Robledo K., Yip S., Cummins M., Smith D., et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 2021;9(6):e002255. DOI: 10.1136/jitc-2020-002255

32. Aghajanian C., Sill M.W., Darcy K.M., Greer B., McMeekin D.S., Rose P.G., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65. DOI: 10.1200/JCO.2010.32.6397

33. Spirtos N.M., Enserro D., Homesley H.D., Gibbons S.K., Cella D., Morris R.T., et al. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2019 Jul;154(1):13–21. doi: 10.1016/j.ygyno.2019.03.240

34. Motzer R.J., Hutson T.E., Glen H., Michaelson M.D., Molina A., Eisen T., et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. DOI: 10.1016/S1470-2045(15)00290-9

35. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32. DOI: 10.1056/NEJMoa1503093

36. Schlumberger M., Tahara M., Wirth L.J., Robinson B., Brose M.S., Elisei R., et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30. DOI: 10.1056/NEJMoa1406470

37. Marcus L., Lemery S.J., Keegan P., Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instabilityhigh solid tumors. Clin Cancer Res. 2019;25(13):3753–8. DOI: 10.1158/1078-0432.CCR-18-4070

38. Marth C., Tarnawski R., Tyulyandina A., Pignata S., Gilbert L., Kaen D., et al. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022;32(1):93–100. DOI: 10.1136/ijgc-2021-003017

39. Makker V., Colombo N., Casado Herráez A., Santin A.D., Colomba E., Miller D.S., et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–48. DOI: 10.1056/NEJMoa2108330

40. McMeekin S., Dizon D., Barter J., Scambia G., Manzyuk L., Lisyanskaya A., et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138(1):18–23. DOI: 10.1016/j.ygyno.2015.04.026

41. Miller D.S., Scambia G., Bondarenko I., Westermann A.M., Oaknin A., Oza A.M., et al. ZoptEC: phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer. J Clin Oncol. 2018;36(Suppl 15):5503. DOI: 10.1200/JCO.2018.36.15_suppl.5503

42. Fala L. Lenvima (Lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the FDA for the treatment of patients with differentiated thyroid cancer. Am Health Drug Benefits. 2015;8(Spec Feature):176–9. PMID: 26629286

43. Robert C., Ribas A., Schachter J., Arance A., Grob J.J., Mortier L., et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. DOI: 10.1016/S1470-2045(19)30388-2

44. How J.A., Patel S., Fellman B., Lu K.H., Hwu P., Ramondetta L.M., et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021;162(1):24–31. DOI: 10.1016/j.ygyno.2021.04.034

45. Pal S.K., Puente J., Chin Heng D.Y., Glen H., Koralewski P., Stroyakovskiy D., et al. Phase 2 trial of lenvatinib at 2 starting doses + everolimus in renal cell carcinoma (RCC). Kidney Cancer J. 2020;18(Suppl 4):34–5. DOI: 10.1200/JCO.2021.39.6_suppl.307

46. Brose M.S., Panaseykin Y., Konda B., de la Fouchardiere C., Hughes B.G.M., Gianoukakis A.G., et al. A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J Clin Endocrinol Metab. 2022;107(3):776–87. DOI: 10.1210/clinem/dgab731